Related Experiment Video
Updated: Jun 25, 2026
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Cost analysis of iron-related complications in a single institute
Ki Hwan Kim1, Jin Won Kim, Ji Young Rhee
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Insights
Caring for iron-related complications (IRCs) incurs significant medical costs in Korea. More effective iron-chelating therapies and further health economic studies are needed to improve patient care and inform policy decisions.
Area of Science:
- Hematology
- Medical Economics
- Public Health
Background:
- Iron-related complications (IRCs) represent a growing financial burden in healthcare, mirroring trends seen in Western countries.
- Understanding the economic impact of IRCs is crucial for developing effective management strategies.
Purpose of the Study:
- To estimate the preliminary costs associated with treating patients experiencing iron-related complications in Korea.
- To highlight the need for improved iron management and further economic evaluations.
Main Methods:
- Retrospective review of medical records for patients receiving multiple blood transfusions (≥10 units of red blood cells).
- Definition of IRCs including cardiomyopathy, heart failure, diabetes mellitus, liver cirrhosis, and liver cancer.
- Calculation of direct medical costs related to laboratory studies, medications, oxygenation, interventions, and patient education.
Main Results:
- Seven patients developed IRCs among 650 hematologic disease patients receiving multiple transfusions between 2002-2006.
- The identified IRCs were liver cirrhosis (2 patients), heart failure (4 patients), and diabetes mellitus (3 patients).
- The total estimated cost for treating IRCs in these seven patients was 47,388,241 KRW (approx. $50,000 USD).
Conclusions:
- The medical costs associated with IRCs are substantial, underscoring the need for more effective iron-chelating therapies.
- Comprehensive health and economic studies are essential for informed decision-making by clinicians and health policymakers regarding IRC management.
Background/Aims:
The financial burden of caring for iron-related complications (IRCs) is an emerging medical problem in Korea, as in Western countries. We produced a preliminary estimate of the costs of treating patients for IRCs.
Methods:
The medical records of patients who had received multiple transfusions were reviewed. Newly developed cardiomyopathy, heart failure, diabetes mellitus, liver cirrhosis, and liver cancer were defined as IRCs. The costs of laboratory studies, medication, oxygenation, intervention, and education were calculated using working criteria we defined. Costs that had a definite causal relationship with IRCs were included to produce as accurate an estimate as possible.
Results:
Between 2002 and 2006, 650 patients with hematologic diseases, including 358 with acute leukemia, 102 with lymphoma, 58 with myelodysplastic syndrome or myeloproliferative disease, 46 with multiple myeloma, and 31 with chronic leukemia, received more than 10 units of red blood cells. Nine patients developed IRCs. The primary diagnoses of eight patients were aplastic anemia and that of one patient was chronic lymphocytic leukemia. Two patients who had diabetes were excluded because one was treated at another hospital and the other was diagnosed as oxymetholone-induced diabetes. Of the seven patients included, liver cirrhosis developed in two, heart failure in four, and diabetes mellitus in three. Some of them had two diagnoses. The total cost attributed to IRCs for the seven patients was 47,388,241 KRW (approximately 50,000 USD).
Conclusions:
The medical costs of IRCs are considerable, and more effective iron-chelating therapy is necessary to save medical resources and improve patient care. More in the way of comprehensive health and economic studies of IRCs are needed to allow both clinicians and health-policy makers to make better decisions.
